Emerging Isotopes Pipeline Analysis and Global Market - Forecast To 2029

2.1 Report Scope
2.2 Report Description
2.3 Pipeline Analysis
2.4 Key Players Analysis
2.5 Stakeholders
2.6 Research Methodology

3.1 Introduction
3.2 Pipeline Analysis Overview
3.2.1 Diagnostic Isotopes Pipeline Analysis
3.2.2 Therapeutic Isotopes Pipeline Analysis
3.3 Demand Analysis of Emerging Isotopes
3.4 Lutetium (Lu-177)
3.4.1 Gep-Net Market Analysis
3.4.2 Prostate Cancer Market Analysis
3.4.3 Lutetium Pipeline Analysis
3.4.3.1 Demand and Production Analysis of Lutetium-177 (Lu-177)
3.4.4 Lu-177 - Deals, Approvals, and Funding
3.5 Gallium (Ga-68)
3.5.1 Supply Chain Analysis of Gallium-68 (Ga-68)
3.5.2 Ga-68 Market Characteristics of Current Ge-68/Ga-68 Generators
3.5.3 Gallium-68 (Ga-68) Pipeline Analysis
3.5.4 Ga-68 - Deals, Approvals, and Funding
3.6 Actinium (Ac-225)
3.6.1 Production Analysis of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213)
3.6.2 Actinium (Ac-225) Pipeline Analysis
3.6.3 Ac-225 - Deals, Approvals, and Funding
3.7 Yttrium (Y-90)
3.7.1 Yttrium (Y-90) Pipeline Analysis
3.7.2 Y-90 - Deals, Approvals, and Funding
3.8 Zirconium (Zr-89)
3.8.1 Zirconium (Zr-89) Pipeline Analysis
3.8.2 Zr-89 - Deals, Approvals, and Funding
3.9 Lead (Pb-212)/Bismuth (Bi-212)
3.9.1 Lead (Pb-212) Pipeline Analysis
3.9.2 Pb-212 - Deals, Approvals, and Funding
3.10 Copper (Cu-64)
3.10.1 Copper 64 (Cu-64) Pipeline Analysis
3.10.2 Cu-64 - Deals, Approvals, and Funding
3.11 Copper (Cu-67)
3.11.1 Copper 67 (Cu-67) Pipeline Analysis
3.11.2 Cu-67 - Deals, Approvals, News, and Funding
3.12 Rhenium (Re-186)
3.12.1 Rhenium (Re-186) Pipeline Analysis
3.12.2 Re-186 - Deals, Approvals, News, and Funding
3.13 Rhenium-188 (Re-188)
3.13.1 Rhenium (Re-188) Pipeline Analysis
3.13.2 Re-188 - Deals, Approvals, News, and Funding
3.14 Astatine (At-211)
3.14.1 Astatine (At-211) Pipeline Analysis
3.14.2 At-211 - Deals, Approvals, News, and Funding
3.15 Holmium (Ho-166)
3.15.1 Holmium (Ho-166) Pipeline Analysis
3.15.2 Ho-166 - Deals, Approvals, and News
3.16 Radium (Ra-223)
3.16.1 Supply Chain Analysis of Radium-223 (Ra-223)
3.16.2 Radium (Ra-223) Pipeline Analysis
3.17 Radium (Ra-224)
3.17.1 Radium (Ra-224) Pipeline Analysis
3.17.2 Ra-224 - Deals, Approvals, News, and Funding
3.18 Thorium (Th-227)
3.18.1 Thorium (Th-227) Pipeline Analysis
3.19 Scandium (Sc-43, 44, 47)
3.20 Terbium (Tb-149,152,155, 161)
3.21 Arsenic (As-72, As-74, As-77)
3.22 Iron (Fe-52)
3.23 Barium-128 (Ba-128)
3.24 Barium-131 (Ba-131)

4.1 Boston Scientific Corporation (Bsc)
4.2 Clarity Pharmaceuticals Limited
4.3 Curium Sas
4.4 Eckert & Ziegler Strahlen- Und Medizintechnik AG (Pentixapharm, Gmbh)
4.5 Fusion Pharmaceuticals, Inc.
4.6 Itm Isotope Technologies Munich Se
4.7 Novartis AG
4.8 Orano Med, LLC
4.9 Plus Theapeutics, Inc.
4.10 Point Biopharma Global, Inc.
4.11 Radiomedix, Inc.
4.12 Telix Pharmaceuticals, Ltd.

Table 1 Emerging Isotopes Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 2 Emerging Isotopes Pipeline Analysis Based on Indications (Cancer)
Table 3 Emerging Isotopes Pipeline Analysis Based on Indications (Non-Cancer)
Table 4 Emerging Isotopes Pipeline Analysis Based on Major Players
Table 5 Emerging Isotopes Pipeline Analysis Based on Universities/Hospitals
Table 6 Diagnostic Isotopes Pipeline Analysis Based on Phases
Table 7 Diagnostics Pipeline Analysis Based on Indications
Table 8 Diagnostics Pipeline Analysis Based on Major Players
Table 9 Diagnostic Isotopes Pipeline Analysis Based on Universities/Hospitals
Table 10 Therapeutic Isotopes Pipeline Analysis Based on Phases
Table 11 Therapeutics Pipeline Analysis Based on Indications
Table 12 Therapeutics Pipeline Analysis Based on Major Players
Table 13 Diagnostic Isotopes Pipeline Analysis Based on Universities/Hospitals
Table 14 Lutetium (Lu-177) Isotope Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 15 Gep-Net Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 16 Gep-Net Number of Doses Sold and Patients Treated During 2022
Table 17 Gep-Net Therapy Eligible Patient Population, Based on Region, (2021-2029) (No.S),
Table 18 Gep-Net Total Addressable Market (Tam) for Gep-Net ($Mn)
Table 19 Gep-Net Total Demand for Doses in Curie
Table 20 Gep-Net Number of Doses Sold
Table 21 Prostate Cancer Global Market Revenue, Based on Region, (2022-2029) ($Mn)
Table 22 Prostate Cancer Number of Doses Sold and Patients Treated During 2022
Table 23 Lu-177 Prostate Cancer Therapy Eligible Patient Population, Based on Region, (2022-2029) (No.S),
Table 24 Lu-177 Prostate Cancer Therapy Total Addressable Market (Tam) (2022-2029)($Mn)
Table 25 Lu-177 Prostate Cancer Total Demand for Doses in Curie (2022-2029)
Table 26 Lu-177 Prostate Cancer Number of Doses Sold
Table 27 Lutetium (Lu-177) Suppliers and Production Capacity
Table 28 Gallium (Ga-68) Isotope Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 29 Gallium (Ga-68) Generator Suppliers and Its Characteristics
Table 30 Actinium (Ac-225) Current and Future Suppliers
Table 31 Yttrium (Y-90) Isotope Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 32 Renal Cancer Global Market Revenue, Based on Region, (2024-2029) ($Mn)
Table 33 Zr-89 Renal Cancer Diagnostic Eligible Patient Population, Based on Region, (2022-2029) (No.S),
Table 34 Zr-89 Renal Cancer Diagnostics Total Addressable Market (Tam) (2022-2029)($Mn)
Table 35 Zr-89 Total Demand for Doses in Curie (2022-2029)
Table 36 Net Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 37 Cu-64 Net Diagnostic Eligible Patient Population, Based on Region, (2021-2029) (No.S),
Table 38 Cu-64 Net Diagnostics Total Addressable Market (Tam) (2021-2029)($Mn)
Table 39 Cu-64 Total Demand for Doses in Curie (2021-2029)
Table 40 Rhenium (Re-186) Isotope Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 41 Astatine (At-211) Current Suppliers
Table 42 Radium (Ra-223) Isotope Global Market Revenue, Based on Region, (2021-2029) ($Mn)

Figure 1 Emerging Isotopes Global Market Revenue, Based on Region, (2021-2029) ($Mn) and Market Share 2022 (%)
Figure 2 Emerging Isotopes Global Market Revenue, Based on Region, (2021-2029) ($Mn), CAGR (%)
Figure 3 Emerging Isotopes Pipeline Analysis Based on Phases
Figure 4 Emerging Isotopes Pipeline Analysis Based on Major Players
Figure 5 Emerging Isotopes Pipeline Analysis Based on Candidates and Application
Figure 6 Diagnostic Isotopes Pipeline Analysis Based on Phases
Figure 7 Diagnostic Isotopes Pipeline Analysis Based on Indications
Figure 8 Diagnostic Isotopes Pipeline Analysis Based on Modality
Figure 9 Therapeutic Isotopes Pipeline Analysis Based on Phases
Figure 10 Therapeutic Isotopes Pipeline Analysis Based on Indications
Figure 11 Therapeutic Isotopes Pipeline Analysis, Based on the Type of Radiation
Figure 12 Global Lu-177 Based Therapy Market Penetration, (2022) (%)
Figure 13 North America Lu-177 Based Therapy Market Penetration, (2022) (%)
Figure 14 Europe Lu-177 Based Therapy Market Penetration, (2022) (%)
Figure 15 Asia-Pacific Lu-177 Based Therapy Market Penetration, (2022) (%)
Figure 16 Row Lu-177 Based Therapy Market Penetration, (2021) (%)
Figure 17 Prostate Cancer Global Market Penetration, (2022) (%)
Figure 18 North America Prostate Cancer Market Penetration, (2022) (%)
Figure 19 Europe Prostate Cancer Market Penetration, (2022) (%)
Figure 20 Asia-Pacific Prostate Cancer Market Penetration, (2022) (%)
Figure 21 Row Prostate Cancer Market Penetration, (2022) (%)
Figure 22 Lu-177 Pipeline Analysis Based on Phases
Figure 23 Lu-177 Pipeline Analysis Based on Indications
Figure 24 Lu-177 Pipeline Analysis Based on Targets
Figure 25 Lu-177 Pipeline Analysis Based on Major Players
Figure 26 Lu-177 Pipeline Analysis Based on Molecule Type
Figure 27 Lu-177 Rit Pipeline Analysis Based on Phases
Figure 28 Lu-177 Rit Pipeline Analysis Based on Indications
Figure 29 Lu-177 Rit Pipeline Analysis Based on Targets
Figure 30 Lu-177 Prrt Pipeline Analysis Based on Phases
Figure 31 Lu-177 Prrt Pipeline Analysis Based on Indications
Figure 32 Lu-177 Prrt Pipeline Analysis Based on Targets
Figure 33 Direct Method (Carrier Added)
Figure 34 Indirect Method (Non-Carrier Added)
Figure 35 Ga-68: Major Players Market Share Analysis (2021) (%)
Figure 36 Supply Chain of Ge-68/Ga-68 Generator
Figure 37 Ga-68 Pipeline Analysis Based on Phases
Figure 38 Ga-68 Pipeline Analysis Based on Indications
Figure 39 Ga-68 Pipeline Analysis Based on Targets
Figure 40 Ga-68 Pipeline Analysis Based on Major Players
Figure 41 Ga-68 Pipeline Analysis Based on Molecule Type
Figure 42 Ac-225 Pipeline Analysis Based on Phases
Figure 43 Ac-225 Pipeline Analysis Based on Indications
Figure 44 Ac-225 Pipeline Analysis Based on Targets
Figure 45 Ac-225 Pipeline Analysis Based on Major Players
Figure 46 Ac-225 Pipeline Analysis Based on Molecule Type
Figure 47 Y-90 Pipeline Analysis Based on Phases
Figure 48 Y-90 Pipeline Analysis Based on Indications
Figure 49 Y-90 Pipeline Analysis Based on Targets
Figure 50 Y-90 Pipeline Analysis Based on Major Players
Figure 51 Y-90 Pipeline Analysis Based on Molecule Type
Figure 52 Zr-89 Pipeline Analysis Based on Phases
Figure 53 Zr-89 Pipeline Analysis Based on Indications
Figure 54 Zr-89 Pipeline Analysis Based on Targets
Figure 55 Zr-89 Pipeline Analysis Based on Major Players
Figure 56 Zr-89 Pipeline Analysis Based on Molecule Type
Figure 57 Pb-212 Pipeline Analysis Based on Phases
Figure 58 Pb-212 Pipeline Analysis Based on Indications
Figure 59 Pb-212 Pipeline Analysis Based on Targets
Figure 60 Pb-212 Pipeline Analysis Based on Major Players
Figure 61 Pb-212 Pipeline Analysis Based on Molecule Type
Figure 62 Cu-64 Pipeline Analysis Based on Phases
Figure 63 Cu-64 Pipeline Analysis Based on Indications
Figure 64 Cu-64 Pipeline Analysis Based on Targets
Figure 65 Cu-64 Pipeline Analysis Based on Major Players
Figure 66 Cu-64 Pipeline Analysis Based on Molecule Type
Figure 67 Rhenium (Re-186) Isotope Global Market Share, Based on Region, (2022 V/S 2029) (%)
Figure 68 Boston Scientific Corporation (Bsc)
Figure 69 Clarity Pharmaceuticals Limited
Figure 70 Curium Sas
Figure 71 Eckert & Ziegler (Pentixapharm, Gmbh)
Figure 72 Fusion Pharmaceuticals, Inc.
Figure 73 Itm (Isotope Technologies Munich)
Figure 74 Novartis AG
Figure 75 Orano Med, LLC
Figure 76 Plus Theapeutics, Inc.
Figure 77 Point Biopharma Global, Inc.
Figure 78 Radiomedix, Inc.
Figure 79 Telix Pharmaceuticals, Ltd.